摘要
目的研究香甲丸治疗晚期胃癌的临床效果及安全性。方法纳入2014年6月~2018年5月在江苏省丹阳市中医院肿瘤科住院或门诊治疗且二线治疗失败的晚期胃癌患者72例,采用随机数字表将其分为实验组和对照组。实验组51例,对照组21例。实验组采用香甲丸联合最佳支持治疗,连服15 d为1疗程,至少2个疗程,直至病情明显进展或不能耐受停药,对照组采用最佳支持治疗。观察两组患者乏力、纳差、数字评价量表(NRS)评分、Karnofsky功能状态(KPS)评分、肿瘤标志物、毒副作用情况及患者的总生存期(OS)。结果实验组,51例患者进入研究,其中2例脱落,49例完成研究;对照组21例均完成本研究。实验组治疗后乏力和纳差的治疗有效率明显高于对照组,差异有高度统计学意义(P<0.01);实验组治疗后NRS评分与对照组比较,差异无统计学意义(P>0.05),实验组治疗后KPS评分高于对照组,差异有统计学意义(P<0.05)。实验组未见明显的血液及肝肾毒副作用,有42.86%的患者肿瘤标志物下降,实验组平均OS长于对照组,差异有统计学意义(P<0.05)。结论香甲丸能有效治疗晚期胃癌,能提高患者生活质量,改善胃癌乏力、纳差症状,一定程度上延长生存期,且无明显毒副作用,值得推广。
Objective To study the clinical efficacy and safety of Xiangjia Pills in the treatment of advanced gastric cancer.Methods Seventy-two patients with advanced gastric cancer who had failed second-line treatment in the Department of Oncology,Danyang Hospital of Traditional Chinese Medicine from June 2014 to May 2018 were included,and they were divided into the experimental group and the control group by random number table.There were 51 cases in the experimental group and 21 cases in the control group.The experimental group was treated with Xiangjia Pills combined with the best supportive treatment,which lasted for 15 consecutive days for one course of treatment,and at least two courses of treatment,until the disease progressed significantly or the drug could not be tolerated.The control group was treated with the best supportive treatment.The fatigue,poor appetite,Numerical rating scale(NRS)score,Karnofsky functional status(KPS)score,tumor markers,toxicity and side effects,and overall survival(OS)of patients in both groups were observed.Results In the experimental group,51 patients entered the study,of which 2 cases fell out and 49 cases completed the study.All 21 patients in the control group completed the study.The effective rates of fatigue and poor appetite after treatment in the experimental group were significantly higher than those in the control group,with highly statistically significant differences(P<0.01).There was no significant difference in NRS score between the experiment group and the control group after treatment(P>0.05).After treatment,the KPS score of the experimental group was higher than that of the control group,with statistically significant difference(P<0.05).No significant blood and liver and kidney toxicity were observed in the experimental group,and 42.86% of the patients had decreased tumor markers.The average OS in the experimental group was longer than that in the control group,with statistically significant difference(P<0.05).Conclusion Xiangjia Pills can effectively treat advanced gastric cancer,increase the quality of life of patients,improve the symptoms of fatigue and poor appetite for gastric cancer.To some extent,the survival period is prolonged,and there is no obvious toxic side effect.It is worthy to promotion.
作者
马继恒
王国方
MA Jiheng;WANG Guofang(Department of Oncology,Danyang Hospital of Traditional Chinese Medicine,Jiangsu Province,Danyang 212300,China)
出处
《中国医药导报》
CAS
2020年第3期115-118,共4页
China Medical Herald
基金
江苏省中医药局科技项目(LZ11166)
江苏省丹阳市社会发展科技支撑计划项目
关键词
香甲丸
晚期胃癌
中药
Xiangjia Pill
Advanced gastric cancer
Traditional Chinese medicine
